Please ensure Javascript is enabled for purposes of website accessibility

Why Novavax Stock Is Jumping Today

By Prosper Junior Bakiny – Updated Jun 29, 2020 at 3:46PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An analyst increased his price target on the shares.

What happened?

Novavax (NVAX 4.30%) is already up by more than 1,800% year to date, but the company's stock still isn't done climbing. At least so says Mayank Mamtani, an analyst with B. Riley FBR, who reiterated a buy rating on Novavax today and gave the company a brand-new price target of $106, up from his previous target of $74.

This news may have been the catalyst for Novavax's shares jumping on Monday: The stock is up by 6.4% as of 3:22 p.m. EDT today.

So what

With several companies rushing to end the pandemic by developing an effective vaccine for COVID-19, Novavax has been one of the leaders in the race. Earlier this month, the company was awarded a grant of $60 million from the U.S. Department of Defense to advance the development of its investigational COVID-19 vaccine, NVX-CoV2373. But Mamtani believes that Novavax could receive even more funding from the government than it already has in its quest to develop a vaccine for the coronavirus. Even without additional outside funding, though, the analyst believes that Novavax has more than enough cash in the bank right now. 

Hand drawing upward pointing graph on a board.

Image source: Getty Images.

In particular, the company recently raised $200 million in gross proceeds when it sold convertible preferred stock to an investment fund affiliated with RA Capital Management in a private offering. The preferred stock is convertible into 4,388,852 shares of Novavax's common stock.

Beyond the company's current financial position, Mamtani holds that the addition of several high-profile executives makes Novavax an even more attractive play. Novavax recently appointed former AstraZeneca executive Filip Dubovsky to the position of chief medical officer, for instance. The combination of all these factors will continue to drive Novavax's stock higher, according to Mamtani.

Now what

There is no question that Novavax has had an incredible run year to date. And if the company makes more progress in its efforts to develop a vaccine for COVID-19, the sky is the limit.

But investors should remember that Novavax's shares will jump off a cliff if the company's potential COVID-19 encounters strong headwinds, such as negative results from clinical trials. For those looking to invest in this biotech stock, it is essential to take a prudent approach. 

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
$19.40 (4.30%) $0.80
AstraZeneca PLC Stock Quote
AstraZeneca PLC
$57.04 (2.68%) $1.49

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.